Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.65 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205386 | 0.83 | GRM5 (0.66) | GRM5EGLN1ALDH1A1KDM4EBACE1 | |
| SCHEMBL182219 | 0.83 | GRM5 (0.62) | GRM5ALKBH2EGLN1ALDH1A1MAPK1 | |
| SCHEMBL7152205 | 0.82 | GRM5 (0.54) | GRM5ALKBH2EGLN1ALDH1A1MAPK1 | |
| SCHEMBL5201721 | 0.80 | GRM5 (1.00) | GRM5ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL14764817 | 0.80 | GRM5 (0.62) | GRM5ALKBH2EGLN1ALDH1A1 | |
| SCHEMBL28543136 | 0.77 | GRM5 (0.49) | GRM5ALKBH2EGLN1PDCD1CD274 | |
| SCHEMBL458419 | 0.77 | NPC1 (0.46) | GRM5ALDH1A1MAPK1L3MBTL1KDM4E | |
| SCHEMBL6450046 | 0.77 | GRM5 (0.49) | GRM5ALKBH2EGLN1ALDH1A1MAPK1 | |
| SCHEMBL21863293 | 0.76 | GRM5 (0.47) | GRM5ALKBH2EGLN1ALDH1A1POLB | |
| SCHEMBL2396469 | 0.74 | CYP11B1 (0.44) | GRM5ALDH1A1MAPK1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | GRM5 4040/4885ALKBH2 2636/4885EGLN1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.